

Covid-19 Impact on Global VEGF/VEGFR Inhibitor Drugs Market Size, Status and Forecast 2020-2026

<https://marketpublishers.com/r/C64CC869716BEN.html>

Date: July 2020

Pages: 93

Price: US\$ 3,900.00 (Single User License)

ID: C64CC869716BEN

Abstracts

VEGF/VEGFR Inhibitor Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global VEGF/VEGFR Inhibitor Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the VEGF/VEGFR Inhibitor Drugs market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

This report also analyzes the impact of Coronavirus COVID-19 on the VEGF/VEGFR Inhibitor Drugs industry.

The key players covered in this study

Pfizer

Novartis AG

GlaxoSmithKline plc

Sanofi

AstraZeneca plc

Bristol-Myers-Squibb Company

Genentech, Inc. (Roche)

Merck & Co., Inc.

Bayer AG

Eli Lilly & Company

Market segment by Type, the product can be split into

Tyrosine Kinase Inhibitors

Monoclonal Antibodies

Others

Market segment by Application, split into

Oncology

Ophthalmology

Others

Market segment by Regions/Countries, this report covers

North America

Europe

China

Japan

Southeast Asia

India

Central & South America

The study objectives of this report are:

To analyze global VEGF/VEGFR Inhibitor Drugs status, future forecast, growth opportunity, key market and key players.

To present the VEGF/VEGFR Inhibitor Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

To strategically profile the key players and comprehensively analyze their development plan and strategies.

To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of VEGF/VEGFR Inhibitor Drugs are as follows:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

- 1.1 Study Scope
- 1.2 Key Market Segments
- 1.3 Players Covered: Ranking by VEGF/VEGFR Inhibitor Drugs Revenue
- 1.4 Covid-19 Implications on Market by Type
 - 1.4.1 Global VEGF/VEGFR Inhibitor Drugs Market Size Growth Rate by Type: 2020 VS 2026
 - 1.4.2 Tyrosine Kinase Inhibitors
 - 1.4.3 Monoclonal Antibodies
 - 1.4.4 Others
- 1.5 Market by Application
 - 1.5.1 Global VEGF/VEGFR Inhibitor Drugs Market Share by Application: 2020 VS 2026
 - 1.5.2 Oncology
 - 1.5.3 Ophthalmology
 - 1.5.4 Others
- 1.6 Coronavirus Disease 2019 (Covid-19): VEGF/VEGFR Inhibitor Drugs Industry Impact
 - 1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
 - 1.6.2 Covid-19 Impact: Commodity Prices Indices
 - 1.6.3 Covid-19 Impact: Global Major Government Policy
- 1.7 Study Objectives
- 1.8 Years Considered

2 GLOBAL GROWTH TRENDS

- 2.1 Covid-19 Implications on Global VEGF/VEGFR Inhibitor Drugs Market Perspective (2015-2026)
- 2.2 Covid-19 Implications on Global VEGF/VEGFR Inhibitor Drugs Growth Trends by Regions
 - 2.2.1 VEGF/VEGFR Inhibitor Drugs Market Size by Regions: 2015 VS 2020 VS 2026
 - 2.2.2 VEGF/VEGFR Inhibitor Drugs Historic Market Share by Regions (2015-2020)
 - 2.2.3 VEGF/VEGFR Inhibitor Drugs Forecasted Market Size by Regions (2021-2026)
- 2.3 Industry Trends and Growth Strategy
 - 2.3.1 Market Top Trends
 - 2.3.2 Market Drivers

- 2.3.3 Market Challenges
- 2.3.4 Porter's Five Forces Analysis
- 2.3.5 VEGF/VEGFR Inhibitor Drugs Market Growth Strategy
- 2.3.6 Primary Interviews with Key VEGF/VEGFR Inhibitor Drugs Players (Opinion Leaders)

3 COVID-19 IMPLICATIONS ON COMPETITION LANDSCAPE BY KEY PLAYERS

- 3.1 Global Top VEGF/VEGFR Inhibitor Drugs Players by Market Size
 - 3.1.1 Global Top VEGF/VEGFR Inhibitor Drugs Players by Revenue (2015-2020)
 - 3.1.2 Global VEGF/VEGFR Inhibitor Drugs Revenue Market Share by Players (2015-2020)
 - 3.1.3 Global VEGF/VEGFR Inhibitor Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.2 Global VEGF/VEGFR Inhibitor Drugs Market Concentration Ratio
 - 3.2.1 Global VEGF/VEGFR Inhibitor Drugs Market Concentration Ratio (CR5 and HHI)
 - 3.2.2 Global Top 10 and Top 5 Companies by VEGF/VEGFR Inhibitor Drugs Revenue in 2019
- 3.3 VEGF/VEGFR Inhibitor Drugs Key Players Head office and Area Served
- 3.4 Key Players VEGF/VEGFR Inhibitor Drugs Product Solution and Service
- 3.5 Date of Enter into VEGF/VEGFR Inhibitor Drugs Market
- 3.6 Mergers & Acquisitions, Expansion Plans

4 COVID-19 IMPLICATIONS ON MARKET SIZE BY TYPE (2015-2026)

- 4.1 Global VEGF/VEGFR Inhibitor Drugs Historic Market Size by Type (2015-2020)
- 4.2 Global VEGF/VEGFR Inhibitor Drugs Forecasted Market Size by Type (2021-2026)

5 COVID-19 IMPLICATIONS ON MARKET SIZE BY APPLICATION (2015-2026)

- 5.1 Global VEGF/VEGFR Inhibitor Drugs Market Size by Application (2015-2020)
- 5.2 Global VEGF/VEGFR Inhibitor Drugs Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA IMPACT OF COVID-19

- 6.1 North America VEGF/VEGFR Inhibitor Drugs Market Size (2015-2020)
- 6.2 VEGF/VEGFR Inhibitor Drugs Key Players in North America (2019-2020)
- 6.3 North America VEGF/VEGFR Inhibitor Drugs Market Size by Type (2015-2020)

6.4 North America VEGF/VEGFR Inhibitor Drugs Market Size by Application (2015-2020)

7 EUROPE IMPACT OF COVID-19

- 7.1 Europe VEGF/VEGFR Inhibitor Drugs Market Size (2015-2020)
- 7.2 VEGF/VEGFR Inhibitor Drugs Key Players in Europe (2019-2020)
- 7.3 Europe VEGF/VEGFR Inhibitor Drugs Market Size by Type (2015-2020)
- 7.4 Europe VEGF/VEGFR Inhibitor Drugs Market Size by Application (2015-2020)

8 CHINA IMPACT OF COVID-19

- 8.1 China VEGF/VEGFR Inhibitor Drugs Market Size (2015-2020)
- 8.2 VEGF/VEGFR Inhibitor Drugs Key Players in China (2019-2020)
- 8.3 China VEGF/VEGFR Inhibitor Drugs Market Size by Type (2015-2020)
- 8.4 China VEGF/VEGFR Inhibitor Drugs Market Size by Application (2015-2020)

9 JAPAN IMPACT OF COVID-19

- 9.1 Japan VEGF/VEGFR Inhibitor Drugs Market Size (2015-2020)
- 9.2 VEGF/VEGFR Inhibitor Drugs Key Players in Japan (2019-2020)
- 9.3 Japan VEGF/VEGFR Inhibitor Drugs Market Size by Type (2015-2020)
- 9.4 Japan VEGF/VEGFR Inhibitor Drugs Market Size by Application (2015-2020)

10 SOUTHEAST ASIA IMPACT OF COVID-19

- 10.1 Southeast Asia VEGF/VEGFR Inhibitor Drugs Market Size (2015-2020)
- 10.2 VEGF/VEGFR Inhibitor Drugs Key Players in Southeast Asia (2019-2020)
- 10.3 Southeast Asia VEGF/VEGFR Inhibitor Drugs Market Size by Type (2015-2020)
- 10.4 Southeast Asia VEGF/VEGFR Inhibitor Drugs Market Size by Application (2015-2020)

11 INDIA IMPACT OF COVID-19

- 11.1 India VEGF/VEGFR Inhibitor Drugs Market Size (2015-2020)
- 11.2 VEGF/VEGFR Inhibitor Drugs Key Players in India (2019-2020)
- 11.3 India VEGF/VEGFR Inhibitor Drugs Market Size by Type (2015-2020)
- 11.4 India VEGF/VEGFR Inhibitor Drugs Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA IMPACT OF COVID-19

12.1 Central & South America VEGF/VEGFR Inhibitor Drugs Market Size (2015-2020)

12.2 VEGF/VEGFR Inhibitor Drugs Key Players in Central & South America (2019-2020)

12.3 Central & South America VEGF/VEGFR Inhibitor Drugs Market Size by Type (2015-2020)

12.4 Central & South America VEGF/VEGFR Inhibitor Drugs Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Pfizer

13.1.1 Pfizer Company Details

13.1.2 Pfizer Business Overview and Its Total Revenue

13.1.3 Pfizer VEGF/VEGFR Inhibitor Drugs Introduction

13.1.4 Pfizer Revenue in VEGF/VEGFR Inhibitor Drugs Business (2015-2020))

13.1.5 Pfizer Recent Development and Reaction to COVID-19

13.2 Novartis AG

13.2.1 Novartis AG Company Details

13.2.2 Novartis AG Business Overview and Its Total Revenue

13.2.3 Novartis AG VEGF/VEGFR Inhibitor Drugs Introduction

13.2.4 Novartis AG Revenue in VEGF/VEGFR Inhibitor Drugs Business (2015-2020)

13.2.5 Novartis AG Recent Development and Reaction to COVID-19

13.3 GlaxoSmithKline plc

13.3.1 GlaxoSmithKline plc Company Details

13.3.2 GlaxoSmithKline plc Business Overview and Its Total Revenue

13.3.3 GlaxoSmithKline plc VEGF/VEGFR Inhibitor Drugs Introduction

13.3.4 GlaxoSmithKline plc Revenue in VEGF/VEGFR Inhibitor Drugs Business (2015-2020)

13.3.5 GlaxoSmithKline plc Recent Development and Reaction to COVID-19

13.4 Sanofi

13.4.1 Sanofi Company Details

13.4.2 Sanofi Business Overview and Its Total Revenue

13.4.3 Sanofi VEGF/VEGFR Inhibitor Drugs Introduction

13.4.4 Sanofi Revenue in VEGF/VEGFR Inhibitor Drugs Business (2015-2020)

13.4.5 Sanofi Recent Development and Reaction to COVID-19

13.5 AstraZeneca plc

13.5.1 AstraZeneca plc Company Details

- 13.5.2 AstraZeneca plc Business Overview and Its Total Revenue
- 13.5.3 AstraZeneca plc VEGF/VEGFR Inhibitor Drugs Introduction
- 13.5.4 AstraZeneca plc Revenue in VEGF/VEGFR Inhibitor Drugs Business (2015-2020)
- 13.5.5 AstraZeneca plc Recent Development and Reaction to COVID-19
- 13.6 Bristol-Myers-Squibb Company
 - 13.6.1 Bristol-Myers-Squibb Company Company Details
 - 13.6.2 Bristol-Myers-Squibb Company Business Overview and Its Total Revenue
 - 13.6.3 Bristol-Myers-Squibb Company VEGF/VEGFR Inhibitor Drugs Introduction
 - 13.6.4 Bristol-Myers-Squibb Company Revenue in VEGF/VEGFR Inhibitor Drugs Business (2015-2020)
 - 13.6.5 Bristol-Myers-Squibb Company Recent Development and Reaction to COVID-19
- 13.7 Genentech, Inc. (Roche)
 - 13.7.1 Genentech, Inc. (Roche) Company Details
 - 13.7.2 Genentech, Inc. (Roche) Business Overview and Its Total Revenue
 - 13.7.3 Genentech, Inc. (Roche) VEGF/VEGFR Inhibitor Drugs Introduction
 - 13.7.4 Genentech, Inc. (Roche) Revenue in VEGF/VEGFR Inhibitor Drugs Business (2015-2020)
 - 13.7.5 Genentech, Inc. (Roche) Recent Development and Reaction to COVID-19
- 13.8 Merck & Co., Inc.
 - 13.8.1 Merck & Co., Inc. Company Details
 - 13.8.2 Merck & Co., Inc. Business Overview and Its Total Revenue
 - 13.8.3 Merck & Co., Inc. VEGF/VEGFR Inhibitor Drugs Introduction
 - 13.8.4 Merck & Co., Inc. Revenue in VEGF/VEGFR Inhibitor Drugs Business (2015-2020)
 - 13.8.5 Merck & Co., Inc. Recent Development and Reaction to COVID-19
- 13.9 Bayer AG
 - 13.9.1 Bayer AG Company Details
 - 13.9.2 Bayer AG Business Overview and Its Total Revenue
 - 13.9.3 Bayer AG VEGF/VEGFR Inhibitor Drugs Introduction
 - 13.9.4 Bayer AG Revenue in VEGF/VEGFR Inhibitor Drugs Business (2015-2020)
 - 13.9.5 Bayer AG Recent Development and Reaction to COVID-19
- 13.10 Eli Lilly & Company
 - 13.10.1 Eli Lilly & Company Company Details
 - 13.10.2 Eli Lilly & Company Business Overview and Its Total Revenue
 - 13.10.3 Eli Lilly & Company VEGF/VEGFR Inhibitor Drugs Introduction
 - 13.10.4 Eli Lilly & Company Revenue in VEGF/VEGFR Inhibitor Drugs Business (2015-2020)

13.10.5 Eli Lilly & Company Recent Development and Reaction to COVID-19

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Disclaimer

15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. VEGF/VEGFR Inhibitor Drugs Key Market Segments

Table 2. Key Players Covered: Ranking by VEGF/VEGFR Inhibitor Drugs Revenue

Table 3. Ranking of Global Top VEGF/VEGFR Inhibitor Drugs Manufacturers by Revenue (US\$ Million) in 2019

Table 4. Global VEGF/VEGFR Inhibitor Drugs Market Size Growth Rate by Type (US\$ Million): 2020 VS 2026

Table 5. Key Players of Tyrosine Kinase Inhibitors

Table 6. Key Players of Monoclonal Antibodies

Table 7. Key Players of Others

Table 8. COVID-19 Impact Global Market: (Four VEGF/VEGFR Inhibitor Drugs Market Size Forecast Scenarios)

Table 9. Opportunities and Trends for VEGF/VEGFR Inhibitor Drugs Players in the COVID-19 Landscape

Table 10. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis

Table 11. Key Regions/Countries Measures against Covid-19 Impact

Table 12. Proposal for VEGF/VEGFR Inhibitor Drugs Players to Combat Covid-19 Impact

Table 13. Global VEGF/VEGFR Inhibitor Drugs Market Size Growth by Application (US\$ Million): 2020 VS 2026

Table 14. Global VEGF/VEGFR Inhibitor Drugs Market Size by Regions (US\$ Million): 2020 VS 2026

Table 15. Global VEGF/VEGFR Inhibitor Drugs Market Size by Regions (2015-2020) (US\$ Million)

Table 16. Global VEGF/VEGFR Inhibitor Drugs Market Share by Regions (2015-2020)

Table 17. Global VEGF/VEGFR Inhibitor Drugs Forecasted Market Size by Regions (2021-2026) (US\$ Million)

Table 18. Global VEGF/VEGFR Inhibitor Drugs Market Share by Regions (2021-2026)

Table 19. Market Top Trends

Table 20. Key Drivers: Impact Analysis

Table 21. Key Challenges

Table 22. VEGF/VEGFR Inhibitor Drugs Market Growth Strategy

Table 23. Main Points Interviewed from Key VEGF/VEGFR Inhibitor Drugs Players

Table 24. Global VEGF/VEGFR Inhibitor Drugs Revenue by Players (2015-2020) (Million US\$)

Table 25. Global VEGF/VEGFR Inhibitor Drugs Market Share by Players (2015-2020)

Table 26. Global Top VEGF/VEGFR Inhibitor Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in VEGF/VEGFR Inhibitor Drugs as of 2019)

Table 27. Global VEGF/VEGFR Inhibitor Drugs by Players Market Concentration Ratio (CR5 and HHI)

Table 28. Key Players Headquarters and Area Served

Table 29. Key Players VEGF/VEGFR Inhibitor Drugs Product Solution and Service

Table 30. Date of Enter into VEGF/VEGFR Inhibitor Drugs Market

Table 31. Mergers & Acquisitions, Expansion Plans

Table 32. Global VEGF/VEGFR Inhibitor Drugs Market Size by Type (2015-2020) (Million US\$)

Table 33. Global VEGF/VEGFR Inhibitor Drugs Market Size Share by Type (2015-2020)

Table 34. Global VEGF/VEGFR Inhibitor Drugs Revenue Market Share by Type (2021-2026)

Table 35. Global VEGF/VEGFR Inhibitor Drugs Market Size Share by Application (2015-2020)

Table 36. Global VEGF/VEGFR Inhibitor Drugs Market Size by Application (2015-2020) (Million US\$)

Table 37. Global VEGF/VEGFR Inhibitor Drugs Market Size Share by Application (2021-2026)

Table 38. North America Key Players VEGF/VEGFR Inhibitor Drugs Revenue (2019-2020) (Million US\$)

Table 39. North America Key Players VEGF/VEGFR Inhibitor Drugs Market Share (2019-2020)

Table 40. North America VEGF/VEGFR Inhibitor Drugs Market Size by Type (2015-2020) (Million US\$)

Table 41. North America VEGF/VEGFR Inhibitor Drugs Market Share by Type (2015-2020)

Table 42. North America VEGF/VEGFR Inhibitor Drugs Market Size by Application (2015-2020) (Million US\$)

Table 43. North America VEGF/VEGFR Inhibitor Drugs Market Share by Application (2015-2020)

Table 44. Europe Key Players VEGF/VEGFR Inhibitor Drugs Revenue (2019-2020) (Million US\$)

Table 45. Europe Key Players VEGF/VEGFR Inhibitor Drugs Market Share (2019-2020)

Table 46. Europe VEGF/VEGFR Inhibitor Drugs Market Size by Type (2015-2020) (Million US\$)

Table 47. Europe VEGF/VEGFR Inhibitor Drugs Market Share by Type (2015-2020)

Table 48. Europe VEGF/VEGFR Inhibitor Drugs Market Size by Application (2015-2020) (Million US\$)

Table 49. Europe VEGF/VEGFR Inhibitor Drugs Market Share by Application (2015-2020)

Table 50. China Key Players VEGF/VEGFR Inhibitor Drugs Revenue (2019-2020) (Million US\$)

Table 51. China Key Players VEGF/VEGFR Inhibitor Drugs Market Share (2019-2020)

Table 52. China VEGF/VEGFR Inhibitor Drugs Market Size by Type (2015-2020) (Million US\$)

Table 53. China VEGF/VEGFR Inhibitor Drugs Market Share by Type (2015-2020)

Table 54. China VEGF/VEGFR Inhibitor Drugs Market Size by Application (2015-2020) (Million US\$)

Table 55. China VEGF/VEGFR Inhibitor Drugs Market Share by Application (2015-2020)

Table 56. Japan Key Players VEGF/VEGFR Inhibitor Drugs Revenue (2019-2020) (Million US\$)

Table 57. Japan Key Players VEGF/VEGFR Inhibitor Drugs Market Share (2019-2020)

Table 58. Japan VEGF/VEGFR Inhibitor Drugs Market Size by Type (2015-2020) (Million US\$)

Table 59. Japan VEGF/VEGFR Inhibitor Drugs Market Share by Type (2015-2020)

Table 60. Japan VEGF/VEGFR Inhibitor Drugs Market Size by Application (2015-2020) (Million US\$)

Table 61. Japan VEGF/VEGFR Inhibitor Drugs Market Share by Application (2015-2020)

Table 62. Southeast Asia Key Players VEGF/VEGFR Inhibitor Drugs Revenue (2019-2020) (Million US\$)

Table 63. Southeast Asia Key Players VEGF/VEGFR Inhibitor Drugs Market Share (2019-2020)

Table 64. Southeast Asia VEGF/VEGFR Inhibitor Drugs Market Size by Type (2015-2020) (Million US\$)

Table 65. Southeast Asia VEGF/VEGFR Inhibitor Drugs Market Share by Type (2015-2020)

Table 66. Southeast Asia VEGF/VEGFR Inhibitor Drugs Market Size by Application (2015-2020) (Million US\$)

Table 67. Southeast Asia VEGF/VEGFR Inhibitor Drugs Market Share by Application (2015-2020)

Table 68. India Key Players VEGF/VEGFR Inhibitor Drugs Revenue (2019-2020) (Million US\$)

Table 69. India Key Players VEGF/VEGFR Inhibitor Drugs Market Share (2019-2020)

Table 70. India VEGF/VEGFR Inhibitor Drugs Market Size by Type (2015-2020) (Million US\$)

- Table 71. India VEGF/VEGFR Inhibitor Drugs Market Share by Type (2015-2020)
- Table 72. India VEGF/VEGFR Inhibitor Drugs Market Size by Application (2015-2020) (Million US\$)
- Table 73. India VEGF/VEGFR Inhibitor Drugs Market Share by Application (2015-2020)
- Table 74. Central & South America Key Players VEGF/VEGFR Inhibitor Drugs Revenue (2019-2020) (Million US\$)
- Table 75. Central & South America Key Players VEGF/VEGFR Inhibitor Drugs Market Share (2019-2020)
- Table 76. Central & South America VEGF/VEGFR Inhibitor Drugs Market Size by Type (2015-2020) (Million US\$)
- Table 77. Central & South America VEGF/VEGFR Inhibitor Drugs Market Share by Type (2015-2020)
- Table 78. Central & South America VEGF/VEGFR Inhibitor Drugs Market Size by Application (2015-2020) (Million US\$)
- Table 79. Central & South America VEGF/VEGFR Inhibitor Drugs Market Share by Application (2015-2020)
- Table 80. Pfizer Company Details
- Table 81. Pfizer Business Overview
- Table 82. Pfizer Product
- Table 83. Pfizer Revenue in VEGF/VEGFR Inhibitor Drugs Business (2015-2020) (Million US\$)
- Table 84. Pfizer Recent Development
- Table 85. Novartis AG Company Details
- Table 86. Novartis AG Business Overview
- Table 87. Novartis AG Product
- Table 88. Novartis AG Revenue in VEGF/VEGFR Inhibitor Drugs Business (2015-2020) (Million US\$)
- Table 89. Novartis AG Recent Development
- Table 90. GlaxoSmithKline plc Company Details
- Table 91. GlaxoSmithKline plc Business Overview
- Table 92. GlaxoSmithKline plc Product
- Table 93. GlaxoSmithKline plc Revenue in VEGF/VEGFR Inhibitor Drugs Business (2015-2020) (Million US\$)
- Table 94. GlaxoSmithKline plc Recent Development
- Table 95. Sanofi Company Details
- Table 96. Sanofi Business Overview
- Table 97. Sanofi Product
- Table 98. Sanofi Revenue in VEGF/VEGFR Inhibitor Drugs Business (2015-2020) (Million US\$)

Table 99. Sanofi Recent Development

Table 100. AstraZeneca plc Company Details

Table 101. AstraZeneca plc Business Overview

Table 102. AstraZeneca plc Product

Table 103. AstraZeneca plc Revenue in VEGF/VEGFR Inhibitor Drugs Business (2015-2020) (Million US\$)

Table 104. AstraZeneca plc Recent Development

Table 105. Bristol-Myers-Squibb Company Company Details

Table 106. Bristol-Myers-Squibb Company Business Overview

Table 107. Bristol-Myers-Squibb Company Product

Table 108. Bristol-Myers-Squibb Company Revenue in VEGF/VEGFR Inhibitor Drugs Business (2015-2020) (Million US\$)

Table 109. Bristol-Myers-Squibb Company Recent Development

Table 110. Genentech, Inc. (Roche) Company Details

Table 111. Genentech, Inc. (Roche) Business Overview

Table 112. Genentech, Inc. (Roche) Product

Table 113. Genentech, Inc. (Roche) Revenue in VEGF/VEGFR Inhibitor Drugs Business (2015-2020) (Million US\$)

Table 114. Genentech, Inc. (Roche) Recent Development

Table 115. Merck & Co., Inc. Business Overview

Table 116. Merck & Co., Inc. Product

Table 117. Merck & Co., Inc. Company Details

Table 118. Merck & Co., Inc. Revenue in VEGF/VEGFR Inhibitor Drugs Business (2015-2020) (Million US\$)

Table 119. Merck & Co., Inc. Recent Development

Table 120. Bayer AG Company Details

Table 121. Bayer AG Business Overview

Table 122. Bayer AG Product

Table 123. Bayer AG Revenue in VEGF/VEGFR Inhibitor Drugs Business (2015-2020) (Million US\$)

Table 124. Bayer AG Recent Development

Table 125. Eli Lilly & Company Company Details

Table 126. Eli Lilly & Company Business Overview

Table 127. Eli Lilly & Company Product

Table 128. Eli Lilly & Company Revenue in VEGF/VEGFR Inhibitor Drugs Business (2015-2020) (Million US\$)

Table 129. Eli Lilly & Company Recent Development

Table 130. Research Programs/Design for This Report

Table 131. Key Data Information from Secondary Sources

Table 132. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global VEGF/VEGFR Inhibitor Drugs Market Share by Type: 2020 VS 2026

Figure 2. Tyrosine Kinase Inhibitors Features

Figure 3. Monoclonal Antibodies Features

Figure 4. Others Features

Figure 5. Global VEGF/VEGFR Inhibitor Drugs Market Share by Application: 2020 VS 2026

Figure 6. Oncology Case Studies

Figure 7. Ophthalmology Case Studies

Figure 8. Others Case Studies

Figure 9. VEGF/VEGFR Inhibitor Drugs Report Years Considered

Figure 10. Global VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth 2015-2026 (US\$ Million)

Figure 11. Global VEGF/VEGFR Inhibitor Drugs Market Share by Regions: 2020 VS 2026

Figure 12. Global VEGF/VEGFR Inhibitor Drugs Market Share by Regions (2021-2026)

Figure 13. Porter's Five Forces Analysis

Figure 14. Global VEGF/VEGFR Inhibitor Drugs Market Share by Players in 2019

Figure 15. Global Top VEGF/VEGFR Inhibitor Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in VEGF/VEGFR Inhibitor Drugs as of 2019)

Figure 16. The Top 10 and 5 Players Market Share by VEGF/VEGFR Inhibitor Drugs Revenue in 2019

Figure 17. North America VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2015-2020) (Million US\$)

Figure 18. Europe VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2015-2020) (Million US\$)

Figure 19. China VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2015-2020) (Million US\$)

Figure 20. Japan VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2015-2020) (Million US\$)

Figure 21. Southeast Asia VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2015-2020) (Million US\$)

Figure 22. India VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2015-2020) (Million US\$)

Figure 23. Central & South America VEGF/VEGFR Inhibitor Drugs Market Size YoY Growth (2015-2020) (Million US\$)

Figure 24. Pfizer Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 25. Pfizer Revenue Growth Rate in VEGF/VEGFR Inhibitor Drugs Business (2015-2020)

Figure 26. Novartis AG Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 27. Novartis AG Revenue Growth Rate in VEGF/VEGFR Inhibitor Drugs Business (2015-2020)

Figure 28. GlaxoSmithKline plc Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 29. GlaxoSmithKline plc Revenue Growth Rate in VEGF/VEGFR Inhibitor Drugs Business (2015-2020)

Figure 30. Sanofi Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 31. Sanofi Revenue Growth Rate in VEGF/VEGFR Inhibitor Drugs Business (2015-2020)

Figure 32. AstraZeneca plc Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 33. AstraZeneca plc Revenue Growth Rate in VEGF/VEGFR Inhibitor Drugs Business (2015-2020)

Figure 34. Bristol-Myers-Squibb Company Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 35. Bristol-Myers-Squibb Company Revenue Growth Rate in VEGF/VEGFR Inhibitor Drugs Business (2015-2020)

Figure 36. Genentech, Inc. (Roche) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 37. Genentech, Inc. (Roche) Revenue Growth Rate in VEGF/VEGFR Inhibitor Drugs Business (2015-2020)

Figure 38. Merck & Co., Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 39. Merck & Co., Inc. Revenue Growth Rate in VEGF/VEGFR Inhibitor Drugs Business (2015-2020)

Figure 40. Bayer AG Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 41. Bayer AG Revenue Growth Rate in VEGF/VEGFR Inhibitor Drugs Business (2015-2020)

Figure 42. Eli Lilly & Company Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 43. Eli Lilly & Company Revenue Growth Rate in VEGF/VEGFR Inhibitor Drugs Business (2015-2020)

Figure 44. Bottom-up and Top-down Approaches for This Report

Figure 45. Data Triangulation

Figure 46. Key Executives Interviewed

I would like to order

Product name: Covid-19 Impact on Global VEGF/VEGFR Inhibitor Drugs Market Size, Status and Forecast 2020-2026

Product link: <https://marketpublishers.com/r/C64CC869716BEN.html>

Price: US\$ 3,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C64CC869716BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

